State of Wisconsin Investment Board increased its holdings in shares of Amedisys Inc (NASDAQ:AMED) by 29.7% in the first quarter, according to its most recent filing with the SEC. The fund owned 97,300 shares of the health services provider’s stock after acquiring an additional 22,300 shares during the period. State of Wisconsin Investment Board’s holdings in Amedisys were worth $11,993,000 at the end of the most recent quarter.
Other hedge funds have also modified their holdings of the company. Alpha Quant Advisors LLC grew its holdings in Amedisys by 137.0% during the 1st quarter. Alpha Quant Advisors LLC now owns 237 shares of the health services provider’s stock worth $29,000 after acquiring an additional 137 shares during the last quarter. Captrust Financial Advisors boosted its stake in shares of Amedisys by 161.8% in the 4th quarter. Captrust Financial Advisors now owns 597 shares of the health services provider’s stock valued at $70,000 after purchasing an additional 369 shares during the last quarter. Meeder Asset Management Inc. boosted its stake in shares of Amedisys by 102.3% in the 1st quarter. Meeder Asset Management Inc. now owns 965 shares of the health services provider’s stock valued at $120,000 after purchasing an additional 488 shares during the last quarter. Advisor Group Inc. boosted its stake in shares of Amedisys by 16.4% in the 1st quarter. Advisor Group Inc. now owns 1,585 shares of the health services provider’s stock valued at $195,000 after purchasing an additional 223 shares during the last quarter. Finally, National Asset Management Inc. bought a new position in Amedisys during the 1st quarter worth approximately $211,000. 86.30% of the stock is owned by hedge funds and other institutional investors.
In related news, Director Jeffrey A. Rideout sold 3,657 shares of the stock in a transaction on Monday, June 10th. The stock was sold at an average price of $116.03, for a total value of $424,321.71. Following the transaction, the director now directly owns 5,554 shares in the company, valued at approximately $644,430.62. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Scott G. Ginn sold 4,872 shares of the stock in a transaction on Monday, June 10th. The stock was sold at an average price of $118.50, for a total value of $577,332.00. The disclosure for this sale can be found here. Insiders have sold a total of 43,165 shares of company stock worth $4,990,556 over the last 90 days. Company insiders own 2.90% of the company’s stock.
Amedisys (NASDAQ:AMED) last posted its quarterly earnings results on Tuesday, April 30th. The health services provider reported $1.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.89 by $0.22. The firm had revenue of $467.34 million for the quarter, compared to analysts’ expectations of $460.83 million. Amedisys had a return on equity of 28.25% and a net margin of 7.14%. The company’s revenue for the quarter was up 17.0% compared to the same quarter last year. During the same period in the prior year, the business earned $0.79 EPS. As a group, sell-side analysts forecast that Amedisys Inc will post 4.08 EPS for the current year.
Several research analysts have commented on the company. BidaskClub downgraded Amedisys from a “strong-buy” rating to a “buy” rating in a research note on Thursday, February 28th. Barclays upped their price objective on Amedisys from $115.00 to $120.00 and gave the company an “equal weight” rating in a research note on Thursday, March 21st. Raymond James raised Amedisys from a “market perform” rating to an “outperform” rating and set a $140.00 price objective for the company in a research note on Thursday, May 2nd. Craig Hallum lowered their price objective on Amedisys from $132.00 to $124.00 and set a “hold” rating for the company in a research note on Friday, March 1st. They noted that the move was a valuation call. Finally, ValuEngine downgraded Amedisys from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, February 27th. Nine investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Amedisys currently has a consensus rating of “Hold” and an average price target of $129.89.
WARNING: This report was published by Ticker Report and is owned by of Ticker Report. If you are reading this report on another domain, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this report can be read at https://www.tickerreport.com/banking-finance/4371373/amedisys-inc-nasdaqamed-shares-bought-by-state-of-wisconsin-investment-board.html.
Amedisys Company Profile
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.
Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys Inc (NASDAQ:AMED).
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.